Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer’s Disease

Publisher： Bentham Science Publishers

E-ISSN： 1996-3181|13|8|1315-1324

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.13, Iss.8, 2014-10, pp. : 1315-1324

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease

By Gauthier S.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1511-1520

Informa Healthcare

Access to resources Recommend Favorite

Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status

By Gottwald M.D.   Rozanski R.I.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1673-1682

Informa Healthcare

Access to resources Recommend Favorite

Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme #946;-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer#39;s Disease

By  

Current Computer - Aided Drug Design, Vol. 13, Iss. 4, 2017-11 ,pp. : 266-274

Bentham Science Publishers

Access to resources Recommend Favorite

Metal-protein attenuating compounds and Alzheimer’s disease

By Ritchie Craig W   Bush Ashley I   Masters Colin L  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 12, 2004-12 ,pp. : 1585-1592

Informa Healthcare

Access to resources Recommend Favorite

Multicomponent Reactions for Multitargeted Compounds for Alzheimer`s Disease

By  

Current Topics in Medicinal Chemistry, Vol. 17, Iss. 31, 2018-02 ,pp. : 3319-3327

Bentham Science Publishers

Access to resources Recommend Favorite